CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 120 target
Drug / intervention
PBSC +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02083718
NCT02083718Phase 2Unknown

G-CSF Mobilized Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant

Nanfang Hospital, Southern Medical University·interventional·Posted Mar 11, 2014·Updated Mar 11, 2014

In Brief

A Phase 2 clinical trial evaluating PBSC and MSCs for Stem Cell Transplantation, Hematopoietic and 2 related conditions. Targeting 120 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the utility of treating patients experiencing poor graft function after allogeneic hematopoietic stem cell transplantation with Granulocyte Colony-Stimulating Factor (G-CSF) mobilized peripheral stem cell combined (PBSC) with ex-vivo-expanded BM-drived mesenchymal stem cells from third-party donors. Our first objective was to evaluate the effect of such treatment on poor graft function, and second object was to investigate the safety of such treatment.

Study Details

Timeline

Phase 2UnknownOverdue
2014201520162017201820192020202120222023202420252026
First PostedMar 11, 2014
Enrollment StartJan 1, 2014
Primary CompletionJan 1, 2016
Study CompletionJan 1, 2017
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 12.3 years ago

Interventions

PBSCbiological

MSCsbiological